Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

790
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
790
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

561
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
561
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

289
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
289
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

512
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
512
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

403
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
403
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

1.5K
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A secondary analysis of the TESTING trial predicted individual patient response to corticosteroid treatment in IgA nephropathy.

Kidney international·2026
Same author

Long-term Outcome of Adult Patients With Membranous Nephropathy Treated With Rituximab.

Kidney international reports·2025
Same author

Erratum to "Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts" [<i>Kidney International Reports</i> Volume 10, Issue 4, April 2025, Pages 1283-1287].

Kidney international reports·2025
Same author

Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts.

Kidney international reports·2025
Same author

Predicting Remission in Antiphospholipase A2 Receptor Antibody-Associated Membranous Nephropathy: A Secondary Analysis of the GEMRITUX, MENTOR, and STARMEN Trials.

Clinical journal of the American Society of Nephrology : CJASN·2025
Same author

Application of the updated International IgA Nephropathy Prediction Tool in children one or two years post-biopsy.

Kidney international·2024

Related Experiment Video

Updated: Mar 9, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

1.0K

Membranous nephropathy: integrating basic science into improved clinical management.

Daniel C Cattran1, Paul E Brenchley2

  • 1Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada.

Kidney International
|January 10, 2017
PubMed
Summary
This summary is machine-generated.

Autoimmune membranous nephropathy (AMN) is now understood to be caused by autoantibodies targeting PLA2R or THSD7A. Measuring these autoantibodies improves diagnosis, prognosis, and treatment strategies for AMN.

Keywords:
glomerulonephritismembranous nephropathynephrotic syndromeproteinuriarenal pathology

More Related Videos

Using 2-Photon Microscopy to Quantify the Effects of Chronic Unilateral Ureteral Obstruction on Glomerular Processes
11:47

Using 2-Photon Microscopy to Quantify the Effects of Chronic Unilateral Ureteral Obstruction on Glomerular Processes

Published on: March 4, 2022

2.7K
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.9K

Related Experiment Videos

Last Updated: Mar 9, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

1.0K
Using 2-Photon Microscopy to Quantify the Effects of Chronic Unilateral Ureteral Obstruction on Glomerular Processes
11:47

Using 2-Photon Microscopy to Quantify the Effects of Chronic Unilateral Ureteral Obstruction on Glomerular Processes

Published on: March 4, 2022

2.7K
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.9K

Area of Science:

  • Nephrology
  • Immunology
  • Autoimmune Diseases

Background:

  • Idiopathic membranous nephropathy (IMN) is a frequent cause of nephrotic syndrome in adults.
  • The autoimmune basis of IMN has been established with the identification of phospholipase A2 receptor (PLA2R) as a key target antigen.
  • A second autoantigen, thrombospondin type 1 domain-containing 7A (THSD7A), has also been identified.

Purpose of the Study:

  • To redefine IMN as primary or autoimmune MN (AMN) based on the presence of anti-PLA2R or anti-THSD7A autoantibodies.
  • To discuss the impact of understanding autoimmune mechanisms on the clinical management of AMN.
  • To review current and emerging therapeutic approaches for AMN.

Main Methods:

  • Identification of glomerular-deposited IgG targeting PLA2R and THSD7A.
  • Quantification of anti-PLA2R autoantibodies in serum using enzyme-linked immunosorbent assays.
  • Immunostaining of biopsy specimens to detect PLA2R and THSD7A in immune complexes.

Main Results:

  • Anti-PLA2R autoantibodies are found in 70-75% of IMN cases, with anti-THSD7A in an additional 5-10%.
  • This reclassifies approximately 80-90% of IMN cases as AMN (anti-PLA2R or anti-THSD7A positive).
  • Secondary MN cases show lower association with these autoantibodies, requiring further definition.

Conclusions:

  • The term AMN, encompassing anti-PLA2R and anti-THSD7A positivity, should replace IMN.
  • Sequential measurement of these autoantibodies allows for more precise diagnosis, prognosis, and personalized treatment of AMN.
  • Knowledge of autoimmune mechanisms and antibody monitoring will enhance clinical management and patient outcomes in AMN.